Synthesis and Evaluation of Anticancer Activity of Indazole Derivatives

Abstract

A novel series of indazole 13a–13j derivatives has been synthesized. Their structures are confirmed by ¹H and ¹³C NMR, and mass spectral analysis. The compounds are tested for their anticancer activity against four human cancer cell lines including A549 (Lung), MCF7 (Breast), A375 (Melanoma), and HT-29 (Colon), using combretastatin-A4 as a positive control. Most of the synthesized compounds demonstrate potent activity against the above cell lines. Here IC₅₀ values of target compounds range from 0.010±0.0042 to 12.8±3.77 μM and the control drug from 0.11±0.02 to 0.93±0.034 μM. The compounds 13a, 13b, 13e, 13g, 13h, and 13j are determined to be more potent than the positive control.